Shilpa Medicare’s acceptance by USFDA of NDA filed by its CDMO partner Unicycive for Oxylanthanum Carbonate

Akums Drugs and Pharmaceuticals posts Q2 FY25 adjusted PAT at Rs. 66.7 Cr

For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore

Vimta Labs reports Q2 FY25 PAT at Rs. 17 Cr

Q2 FY25 Total Income was at Rs. 85.4 crore

KIMS to acquire 3,000 beds in next 5 years in Kerala

The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode

Biocon reports Q2 FY25 net loss at Rs. 16 Cr

Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore

MilliporeSigma invests US$ 76 million to expand ADC manufacturing in North America

Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America

Supriya Lifescience reports 19% revenue increase in Q2 FY25

The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24

Mastek partners Innovaccer to transform value-based care and improve patient experience

This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences

Shilpa Medicare’s CDMO customer gets fast-track designation for its investigational drug candidate

GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally

SK pharmteco invests US$ 260 million to expand global small molecule, peptide production

Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong